Healthcare provider profile · identity verified

Robert Keith Cato, MD

Hospitalist · PHILADELPHIA, PA · NPI 1881626174

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	360	121
Amlodipine Besylate	Amlodipine Besylate	253	82
Omeprazole	Omeprazole	195	66
Levothyroxine Sodium	Levothyroxine Sodium	167	55
Metoprolol Succinate	Metoprolol Succinate	149	49
Gabapentin	Gabapentin	135	41
Rosuvastatin Calcium	Rosuvastatin Calcium	129	47
Albuterol Sulfate Hfa	Albuterol Sulfate	113	34
Simvastatin	Simvastatin	110	33
Zolpidem Tartrate	Zolpidem Tartrate	110	23
Losartan Potassium	Losartan Potassium	108	36
Fluticasone Propionate	Fluticasone Propionate	107	44
Celecoxib	Celecoxib	103	32
Metformin Hcl	Metformin Hcl	99	30
Eliquis	Apixaban	97	27
Lisinopril	Lisinopril	97	28
Hydrochlorothiazide	Hydrochlorothiazide	91	32
Metformin Hcl Er	Metformin Hcl	82	25
Lorazepam	Lorazepam	76	21
Allopurinol	Allopurinol	73	25
Carvedilol	Carvedilol	71	19
Famotidine	Famotidine	66	22
Jardiance	Empagliflozin	60	12
Olmesartan Medoxomil	Olmesartan Medoxomil	59	21
Tamsulosin Hcl	Tamsulosin Hcl	59	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	18
Ezetimibe	Ezetimibe	57	15
Furosemide	Furosemide	57	17
Mounjaro	Tirzepatide	57	12
Duloxetine Hcl	Duloxetine Hcl	56	18
Tramadol Hcl	Tramadol Hcl	52	12
Escitalopram Oxalate	Escitalopram Oxalate	48	14
Xarelto	Rivaroxaban	44	13
Clonazepam	Clonazepam	43	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Prednisone	Prednisone	42	18
Mirtazapine	Mirtazapine	41	13
Pantoprazole Sodium	Pantoprazole Sodium	41	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	39	11
Finasteride	Finasteride	38	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	37	18
Potassium Chloride	Potassium Chloride	35	suppressed
Atenolol	Atenolol	34	12
Bupropion Xl	Bupropion Hcl	34	12
Meloxicam	Meloxicam	33	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	33	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	11
Januvia	Sitagliptin Phosphate	30	suppressed
Sertraline Hcl	Sertraline Hcl	29	12
Pravastatin Sodium	Pravastatin Sodium	28	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	27	suppressed
Nifedipine Er	Nifedipine	27	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	26	suppressed
Chlorthalidone	Chlorthalidone	26	12
Trazodone Hcl	Trazodone Hcl	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	25	suppressed
Irbesartan	Irbesartan	25	suppressed
Lansoprazole	Lansoprazole	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	13
Valsartan	Valsartan	24	11
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	23	suppressed
Doxepin Hcl	Doxepin Hcl	23	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	23	suppressed
Ozempic	Semaglutide	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Trulicity	Dulaglutide	23	suppressed
Ibuprofen	Ibuprofen	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Glimepiride	Glimepiride	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	suppressed
Alprazolam	Alprazolam	20	suppressed
Bumetanide	Bumetanide	20	suppressed
Estradiol	Estradiol	20	suppressed
Amoxicillin	Amoxicillin	19	suppressed
Colchicine	Colchicine	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	16
Metoprolol Tartrate	Metoprolol Tartrate	17	suppressed
Nadolol	Nadolol	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	12
Klor-Con M10	Potassium Chloride	15	suppressed
Mometasone Furoate	Mometasone Furoate	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Febuxostat	Febuxostat	13	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Linzess	Linaclotide	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Tarina Fe 1-20 Eq	Norethindrone-E.Estradiol-Iron	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Xanax	Alprazolam	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Diazepam	Diazepam	11	suppressed
Eplerenone	Eplerenone	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error